留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非小细胞肺癌跳跃性N2淋巴结转移的临床病理特点及预后

张家齐 刘磊 王桂阁 白文梁 李单青

张家齐, 刘磊, 王桂阁, 白文梁, 李单青. 非小细胞肺癌跳跃性N2淋巴结转移的临床病理特点及预后[J]. 协和医学杂志, 2019, 10(3): 272-277. doi: 10.3969/j.issn.1674-9081.2019.03.015
引用本文: 张家齐, 刘磊, 王桂阁, 白文梁, 李单青. 非小细胞肺癌跳跃性N2淋巴结转移的临床病理特点及预后[J]. 协和医学杂志, 2019, 10(3): 272-277. doi: 10.3969/j.issn.1674-9081.2019.03.015
Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. doi: 10.3969/j.issn.1674-9081.2019.03.015
Citation: Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. doi: 10.3969/j.issn.1674-9081.2019.03.015

非小细胞肺癌跳跃性N2淋巴结转移的临床病理特点及预后

doi: 10.3969/j.issn.1674-9081.2019.03.015
详细信息
    通讯作者:

    李单青 电话:010-69152630, E-mail:lidanqing@pumch.cn

  • 中图分类号: R734.2;R-1

Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis

More Information
  • 摘要: 肺癌作为全球肿瘤致死的首要原因, 发病率逐年上升。其主要治疗方式, 尤其对于早期非小细胞肺癌患者, 手术治疗依然占主导地位, 而淋巴结转移状态对于肺癌的分期、预后至关重要。跳跃性N2淋巴结转移比较常见, 且与患者预后密切相关。本文主要归纳非小细胞肺癌跳跃性N2淋巴结转移的临床病理特点及其预后, 以期为临床决策提供一定指导。
    利益冲突  无
  • 图  1  第8版肺癌TNM分期中N分期描述

    注:绿色代表原发病灶;红色代表转移淋巴结

    表  1  不同文献报道的跳跃性N2转移肺癌患者5年生存率

    作者 报道年份 跳跃性N2转移 非跳跃性N2转移 P
    例数 5年生存率
    (%)
    例数 5年生存率
    (%)
    Yazgan[34] 2018 59 51.2 71 21.5 0.001
    Akcay[35] 2017 55 20.0 56 7.4 0.084
    Guerrera[12] 2017 54 42.0 225 44.0 0.840
    Li[13] 2015 45 60.7 132 32.1 0.024
    Sonobe[15] 2013 248 47.8 248 41.7 0.168
    Ohta[32] 2006 50 33.4 44 19.8 0.019
    Prenzel[28] 2004 17 41.0 28 14.0 0.019
    Gawrychowski[36] 2003 23 26.1 41 0 0.002
    Fukuse[37] 2000 30 51.0 57 33.0 0.120
    Oyaizu[38] 1999 76 37.0 102 22.0 0.020
    Yoshino[39] 1996 33 35.0 77 13.0 0.054
    下载: 导出CSV
  • [1] Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC Lung Cancer Staging Project:Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification[J]. J Thorac Oncol, 2016, 11:639-650. doi:  10.1016/j.jtho.2016.01.024
    [2] Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC Lung Cancer Staging Project:Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification[J]. J Thorac Oncol, 2016, 11:666-680. doi:  10.1016/j.jtho.2015.12.113
    [3] Detterbeck FC, Chansky K, Groome P, et al. The IASLC Lung Cancer Staging Project:Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer[J]. J Thorac Oncol, 2016, 11:1433-1446. doi:  10.1016/j.jtho.2016.06.028
    [4] Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification[J]. Chest, 2017, 151:193-203. doi:  10.1016/j.chest.2016.10.010
    [5] Kirsh MM, Kahn DR, Gago O, et al. Treatment of bronchogenic carcinoma with mediastinal metastases[J]. Ann Thorac Surg, 1971, 12:11. doi:  10.1016/S0003-4975(10)65088-6
    [6] Libshitz HI, McKenna RJ, Mountain CF. Patterns of mediastinal metastases in bronchogenic carcinoma[J]. Chest, 1986, 90:229-232. doi:  10.1378/chest.90.2.229
    [7] Isaka M, Kojima H, Takahashi S, et al. Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer:Implications for adjuvant therapy[J]. Lung Cancer, 2018, 115:28-33. doi:  10.1016/j.lungcan.2017.11.014
    [8] Riquet M, Assouad J, Bagan P, et al. Skip mediastinal lymph node metastasis and lung cancer:a particular N2 subgroup with a better prognosis[J]. Ann Thorac Surg, 2005, 79:225-233. doi:  10.1016/j.athoracsur.2004.06.081
    [9] Benoit L, Anusca A, Ortega-Deballon P, et al. Analysis of risk factors for skip lymphatic metastasis and their prognostic value in operated N2 non-small-cell lung carcinoma[J]. Eur J Surg Oncol, 2006, 32:583-587. doi:  10.1016/j.ejso.2006.02.004
    [10] Misthos P, Sepsas E, Athanassiadi K, et al. Skip metastases:analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer[J]. Eur J Cardiothorac Surg, 2004, 25:502-508. doi:  10.1016/j.ejcts.2004.01.025
    [11] 孟迪. N2淋巴结跳跃性转移在肺癌中的临床特点和预后分析[D].杭州: 浙江大学, 2016. http://cdmd.cnki.com.cn/Article/CDMD-10335-1016283757.htm
    [12] Guerrera F, Renaud S, Tabbó F, et al. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcino-mas[J]. Eur J Cardiothorac Surg, 2017, 51:680-688. doi:  10.1093/ejcts/ezw362
    [13] Li H, Hu H, Wang R, et al. Lung adenocarcinoma:Are skip N2 metastases different from non-skip?[J]. J Thorac Cardiovasc Surg, 2015, 150:790-795. doi:  10.1016/j.jtcvs.2015.03.067
    [14] Li GL, Zhu Y, Zheng W, et al. Analysis of factors influencing skip lymphatic metastasis in pN(2) non-small cell lung cancer[J]. Chin J Cancer Res, 2012, 24:340-345. doi:  10.1007/s11670-012-0273-x
    [15] Sonobe M, Date H, Wada H, et al. Prognostic factors after complete resection of pN2 non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2013, 146:788-795. doi:  10.1016/j.jtcvs.2013.04.043
    [16] Takahashi K, Sasaki T, Nabaa B, et al. Pulmonary lymphatic drainage to the mediastinum based on computed tomographic observations of the primary complex of pulmonary histoplasmosis[J]. Acta Radiol, 2012, 53:161-167. doi:  10.1258/ar.2011.110467
    [17] Misthos P, Sepsas E, Kokotsakis J, et al. The significance of one-station N2 disease in the prognosis of patients with nonsmall-cell lung cancer[J]. Ann Thorac Surg, 2008, 86:1626-1630. doi:  10.1016/j.athoracsur.2008.07.076
    [18] Shigemoto Y, Suga K, Matsunaga N. F-18-FDG-avid lymph node metastasis along preferential lymphatic drainage path-ways from the tumor-bearing lung lobe on F-18-FDG PET/CT in patients with non-small-cell lung cancer[J]. Ann Nucl Med, 2016, 30:287-297. doi:  10.1007/s12149-016-1063-1
    [19] Ito M, Yamashita Y, Miyata Y, et al. Prognostic impact of the primary tumor location based on the hilar structures in non-small cell lung cancer with mediastinal lymph node metastasis[J]. Lung Cancer, 2012, 76:93-97. doi:  10.1016/j.lungcan.2011.07.015
    [20] Kawano R, Hata E, Ikeda S, et al. Lobe-specific skip nodal metastasis in non-small cell lung cancer patients[J]. Ann Thorac Cardiovasc Surg, 2008, 14:9-14. https://pubmed.ncbi.nlm.nih.gov/18292733/
    [21] Ilic N, Petricevic A, Arar D, et al. Skip mediastinal nodal metastases in the IIIa/N2 non-small cell lung cancer[J]. J Thorac Oncol, 2007:1018-1021. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_LWW2017052520118368
    [22] Tanaka F, Takenaka K, Oyanagi H, et al. Skip mediastinal nodal metastases in non-small cell lung cancer[J]. Eur J Cardiothorac Surg, 2004, 25:1114-1120. doi:  10.1016/j.ejcts.2004.03.001
    [23] Casali C, Stefani A, Natali P, et al. Prognostic factors in surgically resected N2 non-small cell lung cancer:the impor-tance of patterns of mediastinal lymph nodes metastases[J]. Eur J Cardiothorac Surg, 2005, 28:33-38. doi:  10.1016/j.ejcts.2005.03.016
    [24] 王思愚, 吴一龙, 区伟, 等.非小细胞肺癌纵隔淋巴结跳跃性转移的研究[J].中华肿瘤杂志, 2001, 23:259-261. doi:  10.3760/j.issn:0253-3766.2001.03.028
    [25] Gorai A, Sakao Y, Kuroda H, et al. The clinicopathological features associated with skip N2 metastases in patients with clinical stage IA non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2015, 47:653-658. doi:  10.1093/ejcts/ezu244
    [26] Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small-cell lung carcinoma[J]. N Engl J Med, 1993, 329:690-694. doi:  10.1056/NEJM199309023291003
    [27] Ohsaki Y, Toyoshima E, Fujiuchi S, et al. bcl-2 and p53 protein expression in non-small cell lung cancers:correlation with survival time[J]. Clin Cancer Res, 1996, 2:915-920. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM9816250
    [28] Prenzel KL, Baldus SE, Mönig SP, et al. Skip metastasis in nonsmall cell lung carcinoma[J]. Cancer, 2004, 100:1909-1917. doi:  10.1002/cncr.20165
    [29] Komatsu H, Mizuguchi S, Izumi N, et al. Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer[J]. World J Surg Oncol, 2013, 11:309. doi:  10.1186/1477-7819-11-309
    [30] Takizawa H, Sakiyama S, Tsuboi M, et al. Demonstration of the skip metastasis pathway for N2 non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2014, 147:20022-25223. https://www.sciencedirect.com/science/article/pii/S002252231400035X
    [31] Imai K, Minamiya Y, Saito H, et al. Detection of pleural lymph flow using indocyanine green fluorescence imaging in non-small cell lung cancer surgery:a preliminary study[J]. Surg Today, 2013, 43:249-254. doi:  10.1007/s00595-012-0237-2
    [32] Ohta Y, Shimizu Y, Minato H, et al. Results of initial operations in non-small lung cancer patients with single-level N2 disease[J]. Ann Thorac Surg, 2006, 81:427-433. doi:  10.1016/j.athoracsur.2005.08.018
    [33] Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project:Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours[J]. J Thorac Oncol, 2007, 2:706-714. doi:  10.1097/JTO.0b013e31812f3c1a
    [34] Yazgan S, Ucvet A, Gursoy S, et al. Single-station skip-N2 disease:good prognosis in resected non-small-cell lung cancer (long-term results in skip-N2 disease)[J]. Interact Cardiovasc Thorac Surg, 2019, 28:247-252. doi:  10.1093/icvts/ivy244
    [35] Akcay O. Skip metastasis in non-small cell lung cancer:does it affect the prognosis?[J]. Turk J Thorac Cardiovasc Surg, 2017, 25:230-234. doi:  10.5606/tgkdc.dergisi.2017.13168
    [36] Gawrychowski J, Gabriel A, Lackowska B. Heterogeneity of stage IIIA non-small cell lung cancers (NSCLC) and evaluation of late results of surgical treatment[J]. Eur J Surg Oncol, 2003, 29:178-184. doi:  10.1053/ejso.2002.1321
    [37] Fukuse T, Hirata T, Naiki H, et al. Prognostic significance of proliferative activity in pN2 non-small-cell lung carcinomas and their mediastinal lymph node metastases[J]. Ann Surg, 2000, 232:112-118. doi:  10.1097/00000658-200007000-00016
    [38] Oyaizu T, Sagawa M, Sato M, et al. The pattern of medias-tinal nodal involvement in lung cancer according to tumor-located lobe[J]. Kyobu Geka, 1999, 52:890-894. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM10513151
    [39] Yoshino I, Yokoyama H, Yano T, et al. Skip metastasis to the mediastinal lymph nodes in non-small cell lung cancer[J]. Ann Thorac Surg, 1996, 62:1021-1025. doi:  10.1016/0003-4975(96)00470-5
    [40] Citak N, Sayar A, Metin M, et al. The prognostic signi-ficance of metastasis to lymph nodes in aortopulmonary zone (stations 5 and 6) in completely resected left upper lobe tumors[J]. Thorac Cardiovasc Surg, 2015, 63:568-576. doi:  10.1055/s-0035-1546463
    [41] Cheng X, Zheng D, Li Y, et al. Tumor histology predicts mediastinal nodal status and may be used to guide limited lymphadenectomy in patients with clinical stage I non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2018, 155:2648-2656. doi:  10.1016/j.jtcvs.2018.02.010
    [42] 张翀.临床Ia期非小细胞肺癌纵隔N2淋巴结跳跃性转移的临床、影像和病理相关因素分析[D].杭州: 浙江大学, 2017. http://cdmd.cnki.com.cn/Article/CDMD-10335-1017119097.htm
    [43] 李汉忠, 张玉石, 郑国洋.肿瘤免疫治疗:回顾与展望[J].协和医学杂志, 2018, 9:289-294. doi:  10.3969/j.issn.1674-9081.2018.04.001
    [44] Cavallin F, Alfieri R, Scarpa M, et al. Nodal skip metastasis in thoracic esophageal squamous cell carcinoma:a cohort study[J]. BMC Surg, 2017, 17:49. doi:  10.1186/s12893-017-0247-5
    [45] Choi YY, An JY, Guner A, et al. Skip lymph node metas-tasis in gastric cancer:is it skipping or skipped?[J]. Gastric Cancer, 2016, 19:206-215. doi:  10.1007/s10120-015-0472-5
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  401
  • HTML全文浏览量:  45
  • PDF下载量:  25
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-12-19
  • 刊出日期:  2020-09-18

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!